Highlights
– In SURMOUNT‑1 participants with obesity and prediabetes, tirzepatide (5/10/15 mg weekly) produced dose‑dependent reductions in 10‑year predicted ASCVD and total CVD risk compared with placebo at week 176.
– Predicted 10‑year risk of progression to type 2 diabetes declined markedly with tirzepatide (absolute reductions vs placebo ~13–16 percentage points on CMDS).
– Risk reductions tracked with weight loss and improvements in cardiometabolic parameters; findings support potential broad cardiometabolic benefit of tirzepatide in this population, while definitive clinical outcome data are awaited.
